Table 3 Cytogenetic response Response .... | American Society of Hematology

Table 3

Cytogenetic response

Response	Imatinib resistant		Imatinib intolerant		Total
Response	No.	%	No.	%	No.	%
Response at 24 weeks
All treated patients*	200		88		288
Major†	66	33	24	27	90	31
Complete	45	23	20	23	65	23
Cumulative response
Evaluable patients	186		80		266
Major†	101	54	39	49	140	53
Complete	77	41	33	41	110	41
Reason for exclusion from evaluable analysis
No baseline assessment	14		8		22
Major cytogenetic response† in evaluable patients by dose intensity
Mean dose < 250 mg/d	1/6	17	0/6	0	1/12	8
Mean dose 250 to < 350 mg/d	12/24	50	9/17	53	21/41	51
Mean dose 350 to < 450 mg/d	26/45	58	12/21	57	38/66	58
Mean dose 450 to < 550 mg/d	53/94	56	18/36	50	71/130	55
Mean dose ≥ 550 mg/d	9/17	53	0/0	0	9/17	53

Response	Imatinib resistant		Imatinib intolerant		Total
Response	No.	%	No.	%	No.	%
Response at 24 weeks
All treated patients*	200		88		288
Major†	66	33	24	27	90	31
Complete	45	23	20	23	65	23
Cumulative response
Evaluable patients	186		80		266
Major†	101	54	39	49	140	53
Complete	77	41	33	41	110	41
Reason for exclusion from evaluable analysis
No baseline assessment	14		8		22
Major cytogenetic response† in evaluable patients by dose intensity
Mean dose < 250 mg/d	1/6	17	0/6	0	1/12	8
Mean dose 250 to < 350 mg/d	12/24	50	9/17	53	21/41	51
Mean dose 350 to < 450 mg/d	26/45	58	12/21	57	38/66	58
Mean dose 450 to < 550 mg/d	53/94	56	18/36	50	71/130	55
Mean dose ≥ 550 mg/d	9/17	53	0/0	0	9/17	53

Patients without a baseline or week 24 assessment were counted as nonresponders.

Major cytogenetic response = complete + partial cytogenetic response.